The customer received questionable (b)(6) results for one patient sample from cobas e601 serial number (b)(4).On (b)(6) 2016, the patient was a prospective blood donor and was tested for (b)(6) antibodies with an abbott architect system and the result was (b)(6).The patient was treated with antibiotics.At that time, a test for treponema pallidum particle agglutination assay (tpha) was performed and the result was (b)(6).On (b)(6) 2016 after finishing the antibiotic treatment, the patient again attempted to donate blood.The patient was tested using the roche method and the result from the primary sample tube was (b)(6).On (b)(6) 2016, an aliquot of the sample was retested for confirmation and the (b)(6) was reproduced at (b)(6).A westernblot analysis (viramed) was performed: immuno-blot for (b)(6): (b)(6).Immuno-blot for (b)(6): (b)(6).The patient's (b)(6) result was always (b)(6).No specific data was provided.The doctor in charge was informed about the results, but no action was taken.The patient was not adversely affected.As a consequence of the unclear (b)(6) status of the patient, no blood from the (b)(6) 2016 donation was used and the patient stayed "blocked" for blood donation.
|
Samples from the patient were submitted for investigation.Based on the results of the investigation with multiple testing methods including western blot, tpla, and rpr2, both samples were found to be repeatedly negative/non-reactive.The negative results generated by the customer were determined to be the correct result for the samples.A general reagent issue could be excluded and no product problem was found.
|